Zai Lab (ZLAB) had its price target lowered by JPMorgan Chase & Co. from $39.00 to $32.00. They now have an "overweight" rating on the stock.
Nationwide International Small Cap Fund Q4 2025 Commentary [Seeking Alpha]
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) [Yahoo! Finance]
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight [Yahoo! Finance]